Evidence map›Paper›PMID 38720322›Full record

ArticleJournal of nanobiotechnology2024

Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response.

Yongchao Zha, Li Fu, Zonghua Liu, Jiansheng Lin, Linghong Huang

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yongchao Zha *Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.
Li Fu *Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.
Zonghua LiuDepartment of Biomedical Engineering, Jinan University, Guangzhou, 510632, China. tliuzonghua@jnu.edu.cn.
Jiansheng LinDepartment of Anatomy, Hunan University of Chinese Medicine, Changsha, China. linjiansheng1020@163.com.
Linghong HuangDepartment of Biomedical Engineering, Jinan University, Guangzhou, 510632, China. tohlhong@163.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515012148National Natural Science Foundation of China 82374306Natural Science Foundation of Hunan Province 2023JJ30456Science and Technology Program of Guangzhou, China 202103030004
6 · The paper itself

Abstract

Tumor vaccines, a crucial immunotherapy, have gained growing interest because of their unique capability to initiate precise anti-tumor immune responses and establish enduring immune memory. Injected tumor vaccines passively diffuse to the adjacent draining lymph nodes, where the residing antigen-presenting cells capture and present tumor antigens to T cells. This process represents the initial phase of the immune response to the tumor vaccines and constitutes a pivotal determinant of their effectiveness. Nevertheless, the granularity paradox, arising from the different requirements between the passive targeting delivery of tumor vaccines to lymph nodes and the uptake by antigen-presenting cells, diminishes the efficacy of lymph node-targeting tumor vaccines. This study addressed this challenge by employing a vaccine formulation with a tunable, controlled particle size. Manganese dioxide (MnO

Indexed as

Cancer VaccinesLymph NodesManganese CompoundsMice, Inbred C57BLNanoparticlesOvalbuminOxidesAnimalsAntigens, NeoplasmCell Line, TumorDNAFemaleImmunity, CellularImmunotherapyMelanoma, ExperimentalMiceAntigens, NeoplasmCancer VaccinesDNAManganese Compoundsmanganese dioxideOvalbuminOxidesCellular immunityLymph node targetingTumor immunotherapyTumor vaccines

Identifiers

PMID38720322
PMCPMC11077755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.